DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02472717

PLAQUE

WithdrawnPhase 2

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Clinical Evaluation of Psoriatic Arthritis Treated With Liraglutide. The PLAQUE Study: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

—

actual

Study population

Psoriasis / psoriatic arthritis

Key I/E criterion

—

Primary endpoint

•The proportion of patients achieving an ACR 20% improvement response

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02472717
Org study IDU1111-1150-8501

Timeline

Milestones

Study first posted2015-06-16estimated
Last update posted2017-07-17actual
Study start2015-05 (month precision)
Primary completion2016-10actual (month precision)
Study completion2016-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Psoriasis / psoriatic arthritis

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients with active psoriatic arthritis (3 tender and swollen joints) meeting CASPAR study group criteria

Exclusion criteria

•BMI > 35 kg/m2
•Uncontrolled diabetes, HbA1c > 10.5%
•Current biological treatment for any inflammatory disorder within the past three months
•renal dysfunction (eGFR < 50 ml/min/1.73m or macroalbuminuria >300mg)
•hepatic dysfunction (AST (aspartate aminotransferase), ALT (alanine aminotransferase), Total bilirubin > 3 times upper limit of normal)
•history of pancreatitis or personal or family history of medullary thyroid cancer, c-cell hyperplasia, or MEN-2 syndrome
•current pregnancy or current breast feeding
•use of DPP-4 (dipeptidyl peptidase-4 inhibitor) or GLP-1 receptor agonist within 2 months (washout is permitted)
•drug or alcohol dependence
•resting tachycardia > 100 bpm or conduction abnormalities associated with tachycardia
•current enrollment in any other clinical trial
•symptomatic gastroparesis
•concomitant serious medical conditions
•all medication for the treatment of Psoriatic Arthritis such as MTX (methotrexate) < 25 mg, LFN (leflunomide) < 20 mg, and NSAIDs (non-steroidal anti-inflammatory drugs) will have been used at stable doses for at least 4 weeks, having been initiated at least 3 months prior to study start (8 weeks before screening, 4 weeks before baseline) for MTX and LFN and at least 4 weeks for NSAIDs

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Glycemic / diabetes
1
Cardiometabolic biomarkers
1
Patient-reported / QoL
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

The change in glucose tolerance in patients with psoriatic arthritis with glucose intolerance at baseline who receive liraglutide for 12 weeks compared to those receiving placebo

Time frame:Baseline to 12 weeks

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint/low confidence

The effect(s) of liraglutide on cardiovascular disease risk factors in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo

Time frame:Baseline to 12 weeks

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

The change in quality of life measured by validated quality of life questionnaires in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo

Time frame:Baseline to 12 weeks

change from baseline, improvement

Other clinical outcomes

3 endpoints
Primary/protocol endpoint

The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo

Time frame:Baseline to 12 weeks, liraglutide compared to placebo

threshold achievement, improvement

Secondary/protocol endpoint

The change in the psoriasis area and severity index (PASI) in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to those receiving placebo

Time frame:Baseline to 12 weeks

change from baseline, improvement

Other/protocol endpoint/low confidence

The effect of liraglutide on levels of infiltrating dermal T cells and cytokines in psoriatic skin plaques from patients with psoriatic arthritis receiving liraglutide therapy for 12 weeks compared to those receiving placebo

Time frame:Baseline to 12 weeks

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

The effect(s) of liraglutide on the enumeration of circulating T-cell subpopulations, and on activation of circulating T-cell subpopulations

Time frame:Baseline to 12 weeks

change from baseline, descriptive

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.